Category Archives: ALS Treatment

New science, innovations, and guidelines surrounding resuscitation strategies for sudden cardiac arrest (SCA) develop at a rapid pace, and the Citizen CPR Foundation (CCPRF) is dedicated to ensuring lay rescuers and the healthcare community are kept up to date. CCPRF was founded in 1987 with a vision to strengthen the Chain of Survival following sudden cardiac arrest by educating lay rescuers, dispatchers, EMTs and paramedics, emergency department personnel, and specialists in intensive care units. The foundations biennial Emergency Cardiovascular Care Update (ECCU) Conference transformed into the Cardiac Arrest Survival Summit and this year to simply the Citizen CPR Foundation Virtual Summit, which was held Dec Continue reading →

Israeli cell therapy specialist Neurogenesis Ltd., said new phase II data has shown that treatment with its autologous cell therapy candidate NG-01 in progressive multiple sclerosis (MS) patients led to an 80% to 90% reduction in disease progression at 12 months compared to a pretreatment period and a 90% reduction in relapses compared to placebo-treated patients. The results are highly significant in all parameters and show much more efficacy than any other treatment in progressive MS, Dimitrios Karussis, lead principal investigator and director of the MS Center at Hadassah Medical Center in Jerusalem, told BioWorld. Karussis explained that there are currently very effective medications for stopping relapses and slowing the progression of relapsing remitting MS, but not very successful ones for progressive disease. Continue reading →

The Telegraph Israel announced on Saturday that it is establishing full diplomatic relations with the relatively isolated Himalayan kingdom of Bhutan, the latest in a string of international deals designed to show Israels growing acceptance abroad. The circle of recognition of Israel is widening, said Israeli foreign minister, Gabi Ashkenazi. Continue reading →

Amyotrophic lateral sclerosis (ALS) is a neurological disease and also termed as Lou Gehrigs disease. The disease affects the motor neurons, which control the action of voluntary muscles, as a result the messages between brain and muscle fibers are blocked. ALS could occur in a person due to genetic inheritance, mutation in gene which encodes enzyme copper-zinc superoxide dismutase coupled with defect in chromosome 9. Continue reading →

Oct. Continue reading →

We are pleased with the clinical execution momentum across our portfolio, including the first patient dosed in the registrational AFFINE study of our investigational hemophilia A gene therapy partnered with Pfizer, as well as dosing of the first two patients in the Phase 1/2 STAAR study evaluating our Fabry disease gene therapy, said Sandy Macrae, CEO of Sangamo. We also continue to advance our research projects, exemplified by the completion of our research activities in our ALS program partnered with Pfizer. Business Updates Third Quarter 2020 Financial Results Cash, cash equivalents and marketable securities were $694.6 million as of September 30, 2020, compared to $384.3 million as of December 31, 2019. Continue reading →

TORONTO and CAMBRIDGE, Mass., Oct. 30, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today that co-founder and Chief Scientific Officer Dr. Continue reading →

Two ALS patientsin Australia have been able to control their PCs through direct thought with the implant of a brain-computer interface from Synchron, a biomed startup based in San Francisco. The findings were reported last week in the Journal of NeuroInterventional Surgery and summarized in a press release on the Synchron web site. The interfacea kind of sensor called Stentrode--allowed the patients with severe paralysis to resume tasks such as texting, emailing, and online shopping and banking through direct thought Continue reading →

Only two decades ago, stem cell therapy was highly regulated in the United States and other countries but it was well underway in Hadassah Hospitals labs in Jerusalem. Continue reading →

Global Amyotrophic Lateral Sclerosis Treatment Market By Disease Type (Benign Focal Amyotrophy of ALS, Infantile Spinal Muscular Atrophy, Juvenile Spinal Muscular Atrophy, Kugelberg-Welander Disease, Primary Lateral Sclerosis, Progressive Bulbar Palsy, Spinal Muscular Atrophy, Upper Motor Neuron Disease, Werdnig-Hoffman Disease, Wohlfart-Disease), Drug Type (Riluzole and Edaravone (Radicava)), By Distribution Channel (Hospital Pharmacies, and Retail & Online Pharmacies), Treatment type (Chemotherapy, Stem cell therapy) End- User (Hospitals, Homecare, Specialty Clinics, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends & Forecast to 2026 Get a sample copy of report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-amyotrophic-lateral-sclerosis-treatment-market Few of the major competitors currently working in the amyotrophic lateral sclerosis treatment market are Sanofi (France), Mitsubishi Tanabe Pharma Corporation (Japan), BrainStorm Cell Limited (US), ViroMed Co., Ltd (South Korea), Ionis Pharmaceuticals (US), Genervon Biopharmaceuticals, LLC (US), Biogen (US), ORPHAZYME A/S (Denmark), Orion Pharma (Finland), Kringle Pharma, Inc. (Japan), Aquestive Therapeutics (US), Apotex Inc (Canada), Bausch Health Companies Inc. Continue reading →